Clinical study of anti-relapse after resection of HCC with Licartin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011206

Enrollment

Unknown

Registered

2017-04-20

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatic carcinoma

Interventions

experimental group:Licartin intravenous injection

control group:symptomatic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as HCC; 2. Good compliance and signed informed consent; 3. Generally in good condition, no severe lesions of heart,lung and kidney; 4. Liver function:Child A and Child B; 5. No history of biologic agents; 6. Aged 18-70 years; 7. ECOG 0-2; 8. Single tumor>=5cm or multiple tumors>=3, or vasculature involved.

Exclusion criteria

Exclusion criteria: 1. Poor cardiopulmonary function, can't tolerate surgery; 2. Liver function:Child C; 3. Organ failure:liver,heart,lung and brain; 4. Unawareness or do not cooperate with treatment; 5. Thyroid dysfunctions or can not tolerate thyroid blocking; 6. Disease can disturb the evaluation of the study of Licartin; 7. extrahepatic metastases.

Design outcomes

Primary

Measure	Time frame
TTR;OS;	—

Countries

China

Contacts

Public ContactTan Jingwang

The First Affiliated Hospital of PLA General Hospital

tanjingwang02@aliyun.com+86 13716801336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026